Everything on Biotech Strategy

Pharmaceutical leaders are shifting toward aggressive M&A strategies to counter intensifying GLP-1 competition and regulatory pricing pressure in key markets.

Impact: Companies prioritizing pipeline breadth through strategic acquisitions will maintain market share and pricing power amid saturated therapeutic categories.

— from AI Infrastructure, Direct Sales, and Decentralized Liquidity Shifts · OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News· May 07, 2026